NanosGroup

Clinical trials soon

http://ow.ly/PtsI50urQjK

Beyond the immunity cycle Roche’s scientists are leading pioneers in immune biology and cancer research, which is resulting in innovative and personalised treatment options in cancer

https://www.herbalride.com/pancreatic-health-formula-type-2-diabetes-new/?___store=default

Pancreatic Health Formula Type 2 Diabetes new

https://www.google.com/search?site=&source=hp&q=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3D8iItMi05eIU&oq=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3D8iItMi05eIU&gs_l=psy-ab.12..33i160k1l2.3081.3081.0.5208.3.2.0.0.0.0.142.248.0j2.2.0....0...1.2.64.psy-ab..1.1.142.0.mADM6Xr2zWM

https://www.youtube.com/watch?v=8iItMi05eIU - Google Search

https://www.youtube.com/watch?v=dxpZzbqirr4

H**p oil extract CBD being promoted as alternative health treatment for cancer, epilepsy A 3-year-old Florida girl battling brain cancer is now in San Diego hoping to heal by using a treatment found in a form of ma*****na.

Imaging data reveals nanomedicines in lungs

Contributed by: PneumoNP

An experiment carried out in Spain shows the distribution of an inhaled nanomedicine in rat lungs.
Imaging data reveals nanomedicines in lungs © PneumoNP-CIC BiomaGUNE
The PneumoNP project aims at developing new inhaled nanotherapeutic formulations to combat lung infection. The novel drug is comprised of an antibiotic carried by a nanoparticle. For this project, Spanish researchers from CIC BiomaGUNE track the location of the therapeutic particles in rat airways.

The use of nanoparticles in formulations is anticipated to lengthen the residence time of the drug in lungs. Indeed, it is expected to slow down and control the release of the active molecules. This prevents rapid metabolism and fast clearance. So, the therapeutic effects are expected to increase. Besides, the delivery by inhalation contributes to diminish undesired toxicological and off-target side effects. The results obtained in imaging experiments are essential to establish the appropriate dosage to be used in therapeutic experiments with infected animals and to predict therapeutic efficacy.

The researchers have developed labeling methods to incorporate different radionuclides to the nanocarrier and the antibiotic. Thanks to the different physical properties of the radionuclides, they visualize the spatiotemporal distribution of the nanocarrier and the antibiotic separately. To achieve that they also used complementary in vivo imaging modalities.

This is not the first lawsuit J&J has faced over its antipsychotic medication, Risperdal. In February, a jury in Philadelphia decided that J&J pay $2.5 million in damages for failing to warn that Risperdal could cause gynecomastia, or breast development, in males. That was the first lawsuit to go to trial over Risperdal’s ability to trigger gynecomastia, and J&J currently faces more than 1,000 lawsuits in similar cases, reports FiercePharma.